Exagen logo

ExagenNASDAQ: XGN

Profile

Sector:

Healthcare

Country:

United States

IPO:

19 September 2019

Next earnings report:

18 March 2025

Last dividends:

N/A

Next dividends:

N/A
$52.56 M
-74%vs. 3y high
36%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
78%vs. sector
-77%vs. 3y high
24%vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$2.98+$0.08(+2.76%)

Dividend

No data over the past 3 years
$12.51 M$13.53 M
$12.51 M-$5.03 M

Analysts recommendations

Institutional Ownership

XGN Latest News

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
globenewswire.com14 November 2024 Sentiment: POSITIVE

Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease

Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
seekingalpha.com12 November 2024 Sentiment: NEUTRAL

Exagen, Inc. (NASDAQ:XGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Participants Mark Massaro – BTIG Daniel Brennan - TD Cowen Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to the Exagen Inc. Third Quarter 2024 Earnings Call.

Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
zacks.com12 November 2024 Sentiment: NEUTRAL

Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.31 per share a year ago.

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
globenewswire.com21 October 2024 Sentiment: POSITIVE

CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.

Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?
zacks.com09 August 2024 Sentiment: POSITIVE

Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain
zacks.com08 August 2024 Sentiment: POSITIVE

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
zacks.com05 August 2024 Sentiment: POSITIVE

Exagen Inc. (XGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
globenewswire.com01 August 2024 Sentiment: POSITIVE

CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August.

Exagen to Announce Second Quarter 2024 Results on August 5, 2024
globenewswire.com22 July 2024 Sentiment: POSITIVE

CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).

Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
zacks.com13 June 2024 Sentiment: POSITIVE

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

  • 1(current)

What type of business is Exagen?

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

What sector is Exagen in?

Exagen is in the Healthcare sector

What industry is Exagen in?

Exagen is in the Diagnostics & Research industry

What country is Exagen from?

Exagen is headquartered in United States

When did Exagen go public?

Exagen initial public offering (IPO) was on 19 September 2019

What is Exagen website?

https://www.exagen.com

Is Exagen in the S&P 500?

No, Exagen is not included in the S&P 500 index

Is Exagen in the NASDAQ 100?

No, Exagen is not included in the NASDAQ 100 index

Is Exagen in the Dow Jones?

No, Exagen is not included in the Dow Jones index

When was Exagen the previous earnings report?

No data

When does Exagen earnings report?

The next expected earnings date for Exagen is 18 March 2025